SER (Serina Therapeutics) Stock Based Compensation: $3.91 Mil (TTM As of Mar. 2026)


SER Serina Therapeutics Inc SER
12 GF Score
Price $1.94
! 1 Warning Sign
View Full Analysis

What is Serina Therapeutics Stock Based Compensation?

Serina Therapeutics SER -1.52% 12 Stock Based Compensation is $3.91 Mil as of Mar. 2026. GuruFocus rates SER with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Serina Therapeutics's Stock Based Compensation for the three months ended in Mar. 2026 was $1.08 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was $3.91 Mil.

Serina Therapeutics Stock Based Compensation Related Terms

Serina Therapeutics Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Serina Therapeutics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Serina Therapeutics Stock Based Compensation Chart

Serina Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
0.08 0.01 0.03 2.60 3.79

Serina Therapeutics Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.96 0.89 1.00 0.95 1.08
SER
12GF Score
Serina Therapeutics Inc SER
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Serina Therapeutics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.91 Mil.

What does a Stock Based Compensation of $3.91 Mil mean?
Serina Therapeutics (SER) has a Stock Based Compensation of $3.91 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Serina Therapeutics and its competitors.
Is Serina Therapeutics' Stock Based Compensation too high?
Serina Therapeutics' current Stock Based Compensation is $3.91 Mil. Overall, Serina Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Serina Therapeutics' Stock Based Compensation compare to NRSN and IGC?
Serina Therapeutics' Stock Based Compensation of $3.91 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Serina Therapeutics and its competitors. Serina Therapeutics's current Stock Based Compensation is $3.91 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Serina Therapeutics stock overvalued right now?
Serina Therapeutics (SER) has a current Stock Based Compensation of $3.91 Mil. The current Stock Based Compensation is $3.91 Mil. Serina Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Serina Therapeutics (SER), the current Stock Based Compensation is $3.91 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Serina Therapeutics Business Description

Other Exchanges 2BO:Germany
Address 601 Genome Way, Suite 2001, Huntsville, AL, USA, 35806
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.
12GF Score

Get the complete analysis for SER

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.94
Price